5-Fluorotryptamine

5-Fluorotryptamine
Clinical data
Other names5-Fluoro-T; 5-FT; 5-F-T; PAL-284; PAL284
Drug classSerotonin receptor agonist; Monoamine releasing agent
Identifiers
  • 2-(5-fluoro-1H-indol-3-yl)ethanamine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H11FN2
Molar mass178.210 g·mol−1
3D model (JSmol)
  • C1=CC2=C(C=C1F)C(=CN2)CCN
  • InChI=1S/C10H11FN2/c11-8-1-2-10-9(5-8)7(3-4-12)6-13-10/h1-2,5-6,13H,3-4,12H2
  • Key:ZKIORVIXEWIOGB-UHFFFAOYSA-N

5-Fluorotryptamine (5-fluoro-T, 5-FT, or 5-F-T; code name PAL-284) is a serotonin receptor agonist and monoamine releasing agent of the tryptamine family.

Pharmacology

5-FT is known to have affinity for the serotonin 5-HT1A and 5-HT2A receptors, with Ki values of 18 nM and 6.0–3,908 nM, respectively. It is a full agonist of the serotonin 5-HT2A receptor, with an EC50Tooltip half-maximal effective concentration of 2.64 to 58 nM and an EmaxTooltip half-maximal effective concentration of 110%. The drug is also an agonist of the serotonin 5-HT1A receptor, with an EC50 of 129 nM. 5-HT shows high affinity for the serotonin 5-HT2B and 5-HT2C receptors as well (Ki = 5.7 nM and 3.72 nM, respectively). In addition to its serotonin receptor agonism, 5-FT is a serotonin–dopamine releasing agent (SDRA), with EC50 values for induction of monoamine release of 10.1 nM for serotonin, 82.3 nM for dopamine, and 464 nM for norepinephrine. The drug is also a weak monoamine oxidase inhibitor (MAOI), with IC50Tooltip half-maximal inhibitory concentration values of 13,200 nM for monoamine oxidase A (MAO-A) and 52,500 nM for monoamine oxidase B (MAO-B).

Despite its serotonin 5-HT2A receptor agonism, 5-FT fails to induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, suggesting that it may not have hallucinogenic effects in humans.

Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.

History

5-FT was first described in the scientific literature by 1983.

See also